PharmAlert.net

PharmAlert Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

The FDA ( Food and Drug Administration ) has strengthened the existing warning about the risk of acute kidney injury for the type 2 diabetes medicines Canagliflozin ( Invokana, Invokamet ) and Dapagli ...


The U.S. Food and Drug Administration ( FDA ) has advised that the serious side effects associated with fluoroquinolone antibacterial drugs generally outweigh the benefits for patients with sinusitis, ...


The FDA ( Food and Drug Administration ) has warned about several safety issues with the entire class of opioid pain medicines. These safety risks are potentially harmful interactions with numerous ot ...


The FDA ( Food and Drug Administration ) is eliminating the Risk Evaluation and Mitigation Strategy ( REMS ) for Rosiglitazone-containing type 2 diabetes medicines, which are approved as Avandia, Avan ...


The FDA ( Food and Drug Administration ) is warning that the prescription smoking cessation medicine Chantix ( Varenicline ) can change the way people react to alcohol. Interactions between alcohol a ...


The FDA ( Food and Drug Association ) has concluded a review of a study undertaken to determine the cause of elevated levels of the injectable schizophrenia drug Zyprexa Relprevv ( Olanzapine pamoate ...


The FDA ( Food and Drug Administration ) warned that a case of definite progressive multifocal leukoencephalopathy ( PML ) and a case of probable PML have been reported in patients taking Gilenya ( Fi ...


Fumaric acid esters, which are prescribed for the treatment of psoriasis and multiple sclerosis, are considered to have a favorable risk profile. However, treatment-related progressive multifocal leuk ...


Blincyto ( Blinatumomab ) is indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia ( ALL ). This indication is approved ...


Natalizumab ( Tysabri ), a humanized monoclonal antibody, was approved by the Food and Drug Administration ( FDA ) in 2004 on the basis of interim analysis of two phase III studies, AFFIRM and SENTINE ...


Ibuprofen is a non-steroidal anti-inflammatory drug ( NSAID ) used to treat pain, reduce fever, and relieve inflammation. A safety review was initiated by Health Canada following the publication of a ...


FDA ( Food and Drug Administration ) has strengthened the warning for the type 2 diabetes medicine Canagliflozin ( Invokana, Invokamet ) related to the increased risk of bone fractures, and added new ...


The FDA ( Food and Drug Administration ) is strengthening an existing label warning that non-Aspirin nonsteroidal anti-inflammatory drugs ( NSAIDs ) increase the chance of a myocardial infarction or s ...


Case reports and analyses of clinical studies and of pharmacovigilance data suggest that new oral anticoagulants ( NOACs ) are associated with a small risk for hepatotoxicity. The objective of thi ...


The first non-vitamin K antagonist oral anticoagulant ( NOAC ) introduced to the market in Japan was Dabigatran ( Pradaxa ) in March 2011, and three more NOACs, Rivaroxaban ( Xarelto ), Apixaban ( Eli ...